CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies CPI-613 (6,8-bis[benzylthio]octanoic acid) in treating
patients with relapsed or refractory small cell lung cancer. CPI-613 may interfere with the
growth of tumor cells and may be an effective treatment for small cell lung cancer.